UY35400A - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Info

Publication number
UY35400A
UY35400A UY0001035400A UY35400A UY35400A UY 35400 A UY35400 A UY 35400A UY 0001035400 A UY0001035400 A UY 0001035400A UY 35400 A UY35400 A UY 35400A UY 35400 A UY35400 A UY 35400A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
treatment
present
parasitary
Prior art date
Application number
UY0001035400A
Other languages
English (en)
Inventor
Molteni Valentina
Yeh Vince
Liang Fang
Mishra Pranab
Liying Jocelyn Tan
Jiricek Jan
Mathison Casey
Nagle Advait
Supek Frantisek
Vidal Agnes
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of UY35400A publication Critical patent/UY35400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona compuestos de la fórmula (I) o una sal farmacéuticamente aceptable, tautómero, o estereoisómero, del mismo, donde las variables son como se definen en este documento. La presente invención proporciona además composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de tales compuestos para trata r, prevenir, inhibir, mejorar, o erradicar la patología y/o sintomatología de una enfermedad causada por un parásito, tal como leishmaniasis, tripanosomiasis africana humana y enfermedad de Chagas
UY0001035400A 2013-03-15 2014-03-12 Compuestos y composiciones para el tratamiento de enfermedades parasitarias UY35400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789470P 2013-03-15 2013-03-15
US201461944213P 2014-02-25 2014-02-25

Publications (1)

Publication Number Publication Date
UY35400A true UY35400A (es) 2014-10-31

Family

ID=50625129

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035400A UY35400A (es) 2013-03-15 2014-03-12 Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Country Status (9)

Country Link
US (1) US20160045505A1 (es)
EP (1) EP2970324A1 (es)
BR (1) BR112015023448A2 (es)
CL (1) CL2015002635A1 (es)
IL (1) IL241264A0 (es)
TN (1) TN2015000391A1 (es)
TW (1) TW201522342A (es)
UY (1) UY35400A (es)
WO (1) WO2014151784A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2895239C (en) * 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
TN2016000253A1 (en) 2013-12-19 2017-10-06 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.
NO2699580T3 (es) 2014-01-24 2018-02-24
JP2018516265A (ja) 2015-05-29 2018-06-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 抗寄生虫剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン誘導体
EP3310441B1 (en) 2015-06-18 2020-07-29 89Bio Ltd. 1, 4-substituted piperidine derivatives
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
JP6761821B2 (ja) 2015-07-15 2020-09-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 代謝性グルタミン酸受容体モジュレーターとしてのエチニル誘導体
SI3331885T1 (sl) 2015-08-07 2021-03-31 Glaxosmithkline Intellectual Property Development Limited Spojine
PE20190382A1 (es) 2016-07-18 2019-03-08 Hoffmann La Roche Derivados etinilo
GB201622365D0 (en) * 2016-12-29 2017-02-15 Medical Res Council Tech Compounds
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
CN111587114A (zh) * 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
EP3866773A4 (en) * 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS
ES2937841B2 (es) * 2021-09-30 2023-09-14 Univ Leon Terapia para el tratamiento de la leishmaniosis visceral que comprende nifuratel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ATE380816T1 (de) * 2003-07-30 2007-12-15 S A L V A T Lab Sa Substituierte imidazopyrimidine zur prävention und behandlung von krebs
US9296754B2 (en) * 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
EP2970324A1 (en) 2016-01-20
BR112015023448A2 (pt) 2017-07-18
IL241264A0 (en) 2015-11-30
US20160045505A1 (en) 2016-02-18
TN2015000391A1 (en) 2017-01-03
CL2015002635A1 (es) 2016-02-19
TW201522342A (zh) 2015-06-16
WO2014151784A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
UY35903A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
GT201600123A (es) Inhibidores de syk
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CO2019004034A2 (es) Compuesto de piridina
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
UY36207A (es) Inhibidores de la syk
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
CU20130036A7 (es) Triazina-oxidazoles
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
BR112015014349A2 (pt) derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
UY37569A (es) Inhibidores del inmunoproteasoma
CO2017011969A2 (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211112